Evid Invest

Fair value · BioNTech SE (BNTX) · updated 2026-11-18 · from 20-F FY2025

BioNTech trades at $83.00. That price implies a 2.9% free-cash-flow yield.

Cboe · delayed 15 min · as of 18:26 ET

Statements filed in EUR, converted to USD at the 2025-12-31 period-end rate (0.85106 EUR per USD; ECB reference rates).

Are those assumptions reasonable? Use BNTX’s filed growth history and the AI chat to decide, then set your own inputs below — the range you build is yours.

What the price implies

FCF yield
2.9%

free cash flow ÷ enterprise value (34.3× EV/FCF)

Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings. This price: Cboe · delayed 15 min · as of 18:26 ET.

Inputs come from the FY2025 20-F filed (accession 0001776985-26-000017); set your own on the sliders below. Research, not investment advice.

The filing behind these numbers

BioNTech SE
Revenue
EUR 2.9B
Diluted EPS
EUR -4.70
Free cash flow
EUR 280.9M
operating cash flow − capital expenditure
Diluted shares
241.7M
weighted average

20-F FY2025 · fiscal year ended 2025-12-31 · filed 2026-03-10 · accession 0001776985-26-000017

Open this filing on sec.gov
EvidInvest is an independent research and information tool. Figures are calculated from public SEC filings and third-party market data and are provided for informational and educational purposes only. EvidInvest does not provide investment advice, brokerage, or financial services, and is not affiliated with any company it covers. Verify all figures against primary sources before making any decision.